Tonix Pharmaceuticals (TNXP) vs vTv Therapeutics (VTVT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
vTv Therapeutics (VTVT) has outperformed Tonix Pharmaceuticals (TNXP) over the past year, gaining 36.2% versus a loss of 67.6%. Over five years, VTVT leads with a -47.0% price change compared with -100.0% for TNXP. Tonix Pharmaceuticals is the larger company by market cap ($125.2 million vs $123.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TNXP | VTVT |
|---|---|---|
| Share price | $7.30 | $31.18 |
| Market cap | $125.20M | $123.28M |
| 1-day change | +0.27% | +3.66% |
| YTD return | -53.27% | -22.03% |
| 1-year return | -67.61% | +36.22% |
| 5-year return | -100.00% | -46.97% |
| EPS (TTM) | $-13.06 | $-0.72 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $22.38 | $44.00 |
| 52-week low | $7.10 | $19.50 |
| Distance from 52-week high | -67.38% | -29.14% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +509.59% | +75.47% |
| Average volume | 542.97K | 68.34K |
| Shares outstanding | 17.15M | 3.95M |
| Employees | 142 | 26 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VTVT has outperformed TNXP by 103.8 percentage points over the past year.
About Tonix Pharmaceuticals
TNXP stock →Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia.
Health Care · Biotechnology: Pharmaceutical Preparations · 142 employees
About vTv Therapeutics
VTVT stock →vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 26 employees
TNXP vs VTVT FAQ
Which is bigger, Tonix Pharmaceuticals or vTv Therapeutics?
Tonix Pharmaceuticals (TNXP) is larger, with a market capitalization of $125.20M compared with $123.28M for vTv Therapeutics (VTVT).
Which stock has performed better over the past year, TNXP or VTVT?
VTVT returned +36.22% over the past 12 months, compared with -67.61% for TNXP (price return, excluding dividends). Past performance does not predict future results.
Are Tonix Pharmaceuticals and vTv Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.